Abstract

Hematological malignancies are an aggregate of diverse populations of cells that arise following a complex process of clonal evolution and selection. Recent approaches have facilitated the study of clonal populations and their evolution over time across multiple phenotypic cell populations. In this review, we present current concepts on the role of clonal evolution in leukemic initiation, disease progression, and relapse. We highlight recent advances and unanswered questions about the contribution of the hematopoietic stem cell population to these processes.

REFERENCES

REFERENCES
1.
Kreso
A
,
Dick
JE
.
Evolution of the cancer stem cell model
.
Cell Stem Cell
.
2014
;
14
(
3
):
275
-
291
.
2.
Pastore
F
,
Dufour
A
,
Benthaus
T
, et al
.
Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia
.
J Clin Oncol
.
2014
;
32
(
15
):
1586
-
1594
.
3.
Della Porta
MG
,
Tuechler
H
,
Malcovati
L
, et al
.
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
.
Leukemia
.
2015
;
29
(
7
):
1502
-
1513
.
4.
Döhner
H
,
Estey
E
,
Grimwade
D
, et al
.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
.
Blood
.
2017
;
129
(
4
):
424
-
447
.
5.
Bonnet
D
,
Dick
JE
.
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
.
Nat Med
.
1997
;
3
(
7
):
730
-
737
.
6.
Jan
M
,
Snyder
TM
,
Corces-Zimmerman
MR
, et al
.
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia
.
Sci Transl Med
.
2012
;
4
(
149
):
149ra118
.
7.
Kuo
YH
,
Landrette
SF
,
Heilman
SA
, et al
.
Cbf β-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia
.
Cancer Cell
.
2006
;
9
(
1
):
57
-
68
.
8.
Steidl
U
,
Rosenbauer
F
,
Verhaak
RGW
, et al
.
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells
.
Nat Genet
.
2006
;
38
(
11
):
1269
-
1277
.
9.
Bereshchenko
O
,
Mancini
E
,
Moore
S
, et al
.
Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML
.
Cancer Cell
.
2009
;
16
(
5
):
390
-
400
.
10.
Steidl
U
,
Steidl
C
,
Ebralidze
A
, et al
.
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia
.
J Clin Invest
.
2007
;
117
(
9
):
2611
-
2620
.
11.
Majeti
R
,
Becker
MW
,
Tian
Q
, et al
.
Dysregulated gene expression networks in human acute myelogenous leukemia stem cells
.
Proc Natl Acad Sci USA
.
2009
;
106
(
9
):
3396
-
3401
.
12.
Mitchell
K
,
Barreyro
L
,
Todorova
TI
, et al
.
IL1RAP potentiates multiple oncogenic signaling pathways in AML
.
J Exp Med
.
2018
;
215
(
6
):
1709
-
1727
.
13.
Will
B
,
Zhou
L
,
Vogler
TO
, et al
.
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations
.
Blood
.
2012
;
120
(
10
):
2076
-
2086
.
14.
Shlush
LI
,
Zandi
S
,
Mitchell
A
, et al;
HALT Pan-Leukemia Gene Panel Consortium
.
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia [published correction appears in Nature. 2014;508(7496):420]
.
Nature
.
2014
;
506
(
7488
):
328
-
333
.
15.
Corces-Zimmerman
MR
,
Hong
WJ
,
Weissman
IL
,
Medeiros
BC
,
Majeti
R
.
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
.
Proc Natl Acad Sci USA
.
2014
;
111
(
7
):
2548
-
2553
.
16.
Chen
J
,
Kao
YR
,
Sun
D
, et al
.
Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level [published correction appears in Nat Med. 2019;25(3):529]
.
Nat Med
.
2019
;
25
(
1
):
103
-
110
.
17.
Godley
LA
,
Shimamura
A
.
Genetic predisposition to hematologic malignancies: management and surveillance
.
Blood
.
2017
;
130
(
4
):
424
-
432
.
18.
Gu
X
,
Ebrahem
Q
,
Mahfouz
RZ
, et al
.
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates
.
J Clin Invest
.
2018
;
128
(
10
):
4260
-
4279
.
19.
Busque
L
,
Patel
JP
,
Figueroa
ME
, et al
.
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
.
Nat Genet
.
2012
;
44
(
11
):
1179
-
1181
.
20.
Genovese
G
,
Kähler
AK
,
Handsaker
RE
, et al
.
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
.
N Engl J Med
.
2014
;
371
(
26
):
2477
-
2487
.
21.
Jaiswal
S
,
Fontanillas
P
,
Flannick
J
, et al
.
Age-related clonal hematopoiesis associated with adverse outcomes
.
N Engl J Med
.
2014
;
371
(
26
):
2488
-
2498
.
22.
Bowman
RL
,
Busque
L
,
Levine
RL
.
Clonal hematopoiesis and evolution to hematopoietic malignancies
.
Cell Stem Cell
.
2018
;
22
(
2
):
157
-
170
.
23.
Desai
P
,
Mencia-Trinchant
N
,
Savenkov
O
, et al
.
Somatic mutations precede acute myeloid leukemia years before diagnosis
.
Nat Med
.
2018
;
24
(
7
):
1015
-
1023
.
24.
Abelson
S
,
Collord
G
,
Ng
SWK
, et al
.
Prediction of acute myeloid leukaemia risk in healthy individuals
.
Nature
.
2018
;
559
(
7714
):
400
-
404
.
25.
Luis
TC
,
Wilkinson
AC
,
Beerman
I
,
Jaiswal
S
,
Shlush
LI
.
Biological implications of clonal hematopoiesis
.
Exp Hematol
.
2019
;
77
:
1
-
5
.
26.
Coombs
CC
,
Zehir
A
,
Devlin
SM
, et al
.
Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes
.
Cell Stem Cell
.
2017
;
21
(
3
):
374
-
382.e4
.
27.
Gibson
CJ
,
Lindsley
RC
,
Tchekmedyian
V
, et al
.
Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma
.
J Clin Oncol
.
2017
;
35
(
14
):
1598
-
1605
.
28.
Wong
TN
,
Ramsingh
G
,
Young
AL
, et al
.
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
.
Nature
.
2015
;
518
(
7540
):
552
-
555
.
29.
Lindsley
RC
,
Saber
W
,
Mar
BG
, et al
.
Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation
.
N Engl J Med
.
2017
;
376
(
6
):
536
-
547
.
30.
Lee-Six
H
,
Øbro
NF
,
Shepherd
MS
, et al
.
Population dynamics of normal human blood inferred from somatic mutations
.
Nature
.
2018
;
561
(
7724
):
473
-
478
.
31.
Trumpp
A
,
Essers
M
,
Wilson
A
.
Awakening dormant haematopoietic stem cells
.
Nat Rev Immunol
.
2010
;
10
(
3
):
201
-
209
.
32.
da Silva-Coelho
P
,
Kroeze
LI
,
Yoshida
K
, et al
.
Clonal evolution in myelodysplastic syndromes
.
Nat Commun
.
2017
;
8
(
1
):
15099
.
33.
Mossner
M
,
Jann
JC
,
Wittig
J
, et al
.
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure
.
Blood
.
2016
;
128
(
9
):
1246
-
1259
.
34.
Makishima
H
,
Yoshizato
T
,
Yoshida
K
, et al
.
Dynamics of clonal evolution in myelodysplastic syndromes
.
Nat Genet
.
2017
;
49
(
2
):
204
-
212
.
35.
Stosch
JM
,
Heumüller
A
,
Niemöller
C
, et al
.
Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment
.
Br J Haematol
.
2018
;
182
(
6
):
830
-
842
.
36.
Walter
MJ
,
Shen
D
,
Ding
L
, et al
.
Clonal architecture of secondary acute myeloid leukemia
.
N Engl J Med
.
2012
;
366
(
12
):
1090
-
1098
.
37.
Parkin
B
,
Ouillette
P
,
Li
Y
, et al
.
Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia
.
Blood
.
2013
;
121
(
2
):
369
-
377
.
38.
Ding
L
,
Ley
TJ
,
Larson
DE
, et al
.
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
.
Nature
.
2012
;
481
(
7382
):
506
-
510
.
39.
Jacoby
MA
,
Duncavage
EJ
,
Chang
GS
, et al
.
Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant
.
JCI Insight
.
2018
;
3
(
5
):
e98962
.
40.
Morita
K
,
Wang
F
,
Jahn
K
, et al
.
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
.
Nat Commun
.
2020
;
11
(
1
):
5327
.
doi:10.1101/2020.02.07.925743
41.
Li
S
,
Garrett-Bakelman
FE
,
Chung
SS
, et al
.
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
.
Nat Med
.
2016
;
22
(
7
):
792
-
799
.
42.
Paczulla
AM
,
Rothfelder
K
,
Raffel
S
, et al
.
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion [published correction appears in Nature. 2019;572(7770):E19]
.
Nature
.
2019
;
572
(
7768
):
254
-
259
.
43.
Bell
CC
,
Fennell
KA
,
Chan
YC
, et al
.
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
.
Nat Commun
.
2019
;
10
(
1
):
2723
.
44.
Guo
L
,
Li
J
,
Zeng
H
, et al
.
A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells
.
Nat Commun
.
2020
;
11
(
1
):
740
.
45.
Tenen
DG
.
Disruption of differentiation in human cancer: AML shows the way
.
Nat Rev Cancer
.
2003
;
3
(
2
):
89
-
101
.
46.
Will
B
,
Vogler
TO
,
Narayanagari
S
, et al
.
Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia
.
Nat Med
.
2015
;
21
(
10
):
1172
-
1181
.
47.
Sive
JI
,
Basilico
S
,
Hannah
R
,
Kinston
SJ
,
Calero-Nieto
FJ
,
Göttgens
B
.
Genome-scale definition of the transcriptional programme associated with compromised PU.1 activity in acute myeloid leukaemia
.
Leukemia
.
2016
;
30
(
1
):
14
-
23
.
48.
Jiang
Q
,
Crews
LA
,
Holm
F
,
Jamieson
CHM
.
RNA editing-dependent epitranscriptome diversity in cancer stem cells
.
Nat Rev Cancer
.
2017
;
17
(
6
):
381
-
392
.
49.
Loberg
MA
,
Bell
RK
,
Goodwin
LO
, et al
.
Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis
.
Leukemia
.
2019
;
33
(
7
):
1635
-
1649
.
50.
Thoms
JAI
,
Beck
D
,
Pimanda
JE
.
Transcriptional networks in acute myeloid leukemia
.
Genes Chromosomes Cancer
.
2019
;
58
(
12
):
859
-
874
.
51.
Prieto
C
,
Kharas
MG
.
RNA regulators in leukemia and lymphoma
.
Cold Spring Harb Perspect Med
.
2020
;
10
(
5
):
a034967
.
52.
DeGregori
J
.
Connecting cancer to its causes requires incorporation of effects on tissue microenvironments
.
Cancer Res
.
2017
;
77
(
22
):
6065
-
6068
.
53.
Barreyro
L
,
Chlon
TM
,
Starczynowski
DT
.
Chronic immune response dysregulation in MDS pathogenesis
.
Blood
.
2018
;
132
(
15
):
1553
-
1560
.
54.
Pietras
EM
.
Inflammation: a key regulator of hematopoietic stem cell fate in health and disease
.
Blood
.
2017
;
130
(
15
):
1693
-
1698
.
55.
Verovskaya
EV
,
Dellorusso
PV
,
Passegué
E
.
Losing sense of self and surroundings: hematopoietic stem cell aging and leukemic transformation
.
Trends Mol Med
.
2019
;
25
(
6
):
494
-
515
.
56.
King
KY
,
Huang
Y
,
Nakada
D
,
Goodell
MA
.
Environmental influences on clonal hematopoiesis
.
Exp Hematol
.
2020
;
83
:
66
-
73
.
57.
Cook
EK
,
Luo
M
,
Rauh
MJ
.
Clonal hematopoiesis and inflammation: partners in leukemogenesis and comorbidity
.
Exp Hematol
.
2020
;
83
:
85
-
94
.
58.
Jongen-Lavrencic
M
,
Grob
T
,
Hanekamp
D
, et al
.
Molecular minimal residual disease in acute myeloid leukemia
.
N Engl J Med
.
2018
;
378
(
13
):
1189
-
1199
.
59.
Beer
PA
,
Jones
AV
,
Bench
AJ
, et al
.
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones
.
Br J Haematol
.
2009
;
144
(
6
):
904
-
908
.
60.
Beer
PA
,
Delhommeau
F
,
LeCouédic
JP
, et al
.
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm
.
Blood
.
2010
;
115
(
14
):
2891
-
2900
.
61.
Van Egeren
D
,
Escabi
J
,
Nguyen
M
, et al
. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in JAK2-mutant myeloproliferative neoplasms. bioRxiv.
2020
;.
62.
Williams
N
,
Lee
J
,
Moore
L
, et al
Phylogenetic reconstruction of adult blood cancer reveals early origins and lifelong evolution.
bioRxiv
.
2020
. .
63.
Estey
E
,
Keating
MJ
,
Pierce
S
,
Stass
S
.
Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia
.
Leukemia
.
1995
;
9
(
6
):
972
-
976
.
64.
Krönke
J
,
Bullinger
L
,
Teleanu
V
, et al
.
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
.
Blood
.
2013
;
122
(
1
):
100
-
108
.
65.
Garg
M
,
Nagata
Y
,
Kanojia
D
, et al
.
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse
.
Blood
.
2015
;
126
(
22
):
2491
-
2501
.
66.
Ng
SWK
,
Mitchell
A
,
Kennedy
JA
, et al
.
A 17-gene stemness score for rapid determination of risk in acute leukaemia
.
Nature
.
2016
;
540
(
7633
):
433
-
437
.
67.
Pollyea
DA
,
Jordan
CT
.
Therapeutic targeting of acute myeloid leukemia stem cells
.
Blood
.
2017
;
129
(
12
):
1627
-
1635
.
68.
Tehranchi
R
,
Woll
PS
,
Anderson
K
, et al
.
Persistent malignant stem cells in del(5q) myelodysplasia in remission
.
N Engl J Med
.
2010
;
363
(
11
):
1025
-
1037
.
69.
Hoggatt
J
,
Kfoury
Y
,
Scadden
DT
.
Hematopoietic stem cell niche in health and disease
.
Annu Rev Pathol
.
2016
;
11
(
1
):
555
-
581
.
70.
Mitchell
K
,
Steidl
U
.
Targeting immunophenotypic markers on leukemic stem cells: How lessons from current approaches and advances in the leukemia stem cell (LSC) model can inform better strategies for treating acute myeloid leukemia (AML)
.
Cold Spring Harb Perspect Med
.
2020
;
10
(
1
):
a036251
.
71.
Méndez-Ferrer
S
,
Bonnet
D
,
Steensma
DP
, et al
.
Bone marrow niches in haematological malignancies
.
Nat Rev Cancer
.
2020
;
20
(
5
):
285
-
298
.
72.
Yamashita
M
,
Dellorusso
PV
,
Olson
OC
,
Passegué
E
.
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
.
Nat Rev Cancer
.
2020
;
20
(
7
):
365
-
382
.
73.
Miller
CA
,
White
BS
,
Dees
ND
, et al
.
SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution
.
PLoS Comput Biol
.
2014
;
10
(
8
):
e1003665
.
doi:10.1371/journal.pcbi.1003665
74.
Shlush
LI
,
Mitchell
A
,
Heisler
L
, et al
.
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
.
Nature
.
2017
;
547
(
7661
):
104
-
108
.
75.
Quek
L
,
David
MD
,
Kennedy
A
, et al
.
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
.
Nat Med
.
2018
;
24
(
8
):
1167
-
1177
.
76.
Simonsen
AT
,
Bill
M
,
Rosenberg
CA
, et al
.
Unraveling clonal heterogeneity at the stem cell level in myelodysplastic syndrome: In pursuit of cell subsets driving disease progression
.
Leuk Res
.
2020
;
92
:
106350
.
77.
Ferrando
AA
,
López-Otín
C
.
Clonal evolution in leukemia
.
Nat Med
.
2017
;
23
(
10
):
1135
-
1145
.
78.
Loh
JW
,
Khiabanian
H
.
Leukemia’s clonal evolution in development, progression, and relapse
.
Curr Stem Cell Rep
.
2019
;
5
(
2
):
73
-
81
.
79.
Miles
LA
,
Bowman
RL
,
Merlinsky
TR
, et al
.
Single-cell mutation analysis of clonal evolution in myeloid malignancies
.
Nature
.
2020
;
587
(
7834
):
477
-
482
.
80.
Potter
N
,
Miraki-Moud
F
,
Ermini
L
, et al
.
Single cell analysis of clonal architecture in acute myeloid leukaemia
.
Leukemia
.
2019
;
33
(
5
):
1113
-
1123
.
81.
Cimmino
L
,
Dolgalev
I
,
Wang
Y
, et al
.
Restoration of TET2 function blocks aberrant self-renewal and leukemia progression
.
Cell
.
2017
;
170
(
6
):
1079
-
1095.e20
.
82.
Carvajal
LA
,
Neriah
DB
,
Senecal
A
, et al
.
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
.
Sci Transl Med
.
2018
;
10
(
436
):
eaa3003
.
83.
Konopleva
M
,
Letai
A
.
BCL-2 inhibition in AML: an unexpected bonus?
Blood
.
2018
;
132
(
10
):
1007
-
1012
.
84.
Mullard
A
.
p53 programmes plough on
.
Nat Rev Drug Discov
.
2020
;
19
(
8
):
497
-
500
.
85.
Reynaud
D
,
Pietras
E
,
Barry-Holson
K
, et al
.
IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development
.
Cancer Cell
.
2011
;
20
(
5
):
661
-
673
.
86.
Schinke
C
,
Giricz
O
,
Li
W
, et al
.
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells [published correction appears in Blood. 2015;126(3):425]
.
Blood
.
2015
;
125
(
20
):
3144
-
3152
.
87.
Pietras
EM
,
Mirantes-Barbeito
C
,
Fong
S
, et al
.
Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal
.
Nat Cell Biol
.
2016
;
18
(
6
):
607
-
618
.
88.
Çelik
H
,
Lindblad
KE
,
Popescu
B
, et al
.
Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia
.
Blood Adv
.
2020
;
4
(
2
):
367
-
379
.
89.
Sjövall
D
,
Staffas
A
.
The origin of leukemia: genetic alterations and inflammatory factors in the development of premalignant clonal hematopoiesis
.
Semin Hematol
.
2020
;
57
(
1
):
7
-
12
.
90.
Zhang
TY
,
Dutta
R
,
Benard
B
,
Zhao
F
,
Yin
R
,
Majeti
R
.
IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia
.
Sci Transl Med
.
2020
;
12
(
538
):
eaax5104
.
91.
Illendula
A
,
Pulikkan
JA
,
Zong
H
, et al
.
A small-molecule inhibitor of the aberrant transcription factor CBFβBSMMHC delays leukemia in mice
.
Science
.
2015
;
347
(
6223
):
779
-
784
.
doi:10.1126/science.aaa0314
92.
Stephens
DC
,
Kim
HM
,
Kumar
A
,
Farahat
AA
,
Boykin
DW
,
Poon
GM
.
Pharmacologic efficacy of PU.1 inhibition by heterocyclic dications: a mechanistic analysis
.
Nucleic Acids Res
.
2016
;
44
(
9
):
4005
-
4013
.
93.
Tan
YS
,
Lane
DP
,
Verma
CS
.
Stapled peptide design: principles and roles of computation
.
Drug Discov Today
.
2016
;
21
(
10
):
1642
-
1653
.
94.
Antony-Debré
I
,
Paul
A
,
Leite
J
, et al
.
Pharmacological inhibition of the transcription factor PU.1 in leukemia
.
J Clin Invest
.
2017
;
127
(
12
):
4297
-
4313
.
You do not currently have access to this content.

Sign in via your Institution

Sign In